anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Source Note

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 110,355
Current window 46,351-46,380
Pages 3,679
Rows per page 30
Component: Source Noteclear collectionreset all
18 30 60

Component

46,351-46,380 of 110,355

filter-aware
209
The slide uses a table to contrast the clinical trial design with the author's thesis that the evidence standard is too low.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
210
The slide uses a table of clinical trials alongside red-text annotations to highlight the geographic and temporal distance of the studies.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
211
The slide uses a table from a Lancet paper to argue that pitolisant's performance was inferior to modafinil, contradicting the company's narrative.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
212
The slide uses a pie chart to highlight that 38% of study participants were in Russia, suggesting a lack of geographic diversity and potential data manipulation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
213
The slide uses a combination of narrative text and specific evidence (EMA table and ClinicalTrials.gov record) to prove the existence of a suppressed trial.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
214
The slide uses excerpts from French regulatory documents to prove the existence and negative results of the unpublished HARMONY 4 trial.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
217
The slide uses a screenshot of the ESS website to undermine the credibility of the clinical trial endpoint.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
218
The slide uses visual evidence of four different versions of the ESS form to support the claim that the scale lacks a single, consistent format.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
219
The slide uses a 'villain' framing for the Epworth Sleepiness Scale to justify why it should not be used in the context of the research.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
220
The slide uses a critical tone to re-evaluate clinical trial data, highlighting the gap between statistical results and clinical meaningfulness.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
221
The slide uses clinical trial data to undermine the efficacy claims of a drug by highlighting the placebo response.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
222
The slide uses FDA biometrics review data to challenge the efficacy timeline of the drug Wakix (pitolisant).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
223
The author argues that the discrepancy hides a trend reversal that would undermine the trial's efficacy claims.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
224
The slide uses a 'red flag' argument to suggest data manipulation or p-hacking via sample size adjustment.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
225
The slide uses a strong, accusatory tone to undermine the validity of the clinical trial results.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
226
The slide uses a direct quote from a Lancet letter to undermine the credibility of the HARMONY 1 trial investigators.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
227
The slide highlights a discrepancy between the reported trial results and the underlying patient-level data regarding dosage and efficacy.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
229
The slide highlights a specific regulatory failure/contradiction regarding the acceptance of post-hoc analysis in clinical trials.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
231
The slide uses a 'villain' framing for the FDA reviewer's oversight.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
232
The slide highlights a discrepancy between raw ESS scores and adjusted LS means, accusing the sponsor of data manipulation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
233
The slide uses a combination of a pie chart and two tables to substantiate claims of trial design flaws.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
234
The slide details three specific statistical and methodological reasons for the FDA's rejection of the HARMONY 1 study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
235
The slide uses a strong, accusatory tone ('sycophancy', 'red flags') to frame the FDA's regulatory process as flawed.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
236
The slide uses a pie chart to visualize the geographic concentration of trial participants, specifically pointing out the high percentage in Russia to support a claim of data manipulation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
237
The slide uses a 'villain' framing to discredit the reliability of clinical data originating from Russia and Eastern Europe.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
238
The slide highlights a discrepancy between the trial paper's log-scale chart and the actual linear-scale data, suggesting data manipulation or misleading presentation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
239
The slide highlights the ambiguity in the definition of 'cataplexy' used in the study protocol, leading to potential data reliability issues.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
240
The slide uses ClinicalTrials.gov record history to demonstrate a 'red flag' in trial reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
241
The slide uses red text for emphasis on specific criticisms (dose response, centre effect).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
242
The slide uses a CONSORT-style flow diagram to illustrate patient attrition in a clinical trial.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit